[1] Schrler RW,Arroyo V,Bernardl M,et al.Peripheral arterial vasodilation hypothesis: Aproposal for the initiation of renal sodium and water retention in cirrhosis.Hepatology,1988,8(5):1151-1157.
[2] Gln SP,Sol E,Angeli P,et al.Hepatorenal syndrome.Nat Rev Dis Primers,2018,4(1):23.
[3] Kazory A,Ronco C. Hepatorenal syndrome or hepatocardiorenal syndrome: Revisiting basic concepts in view of emerging data.Cardiorenal Med,2019,9(1):1-7.
[4] Angeli P, Garcia-Tsao G,Mitra K,et al. News in pathophysiology,definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites(ICA) consensus document.J Hepatol,2019,71(4):811-822.
[5] 刘建军,牛蓓.对2017年《肝硬化腹水及相关并发症的诊疗指南》的解读与商榷.新医学杂志,2018,49(1):1-5.
[6] European Association for the Study of the Liver. EASL Clinical practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol,2018,69(2):406-460.
[7] Fuhrmann V,Krowka M. Hepatopulmonary syndrome.J Hepatol,2018,69(3):744-745.
[8] Davenport A,Shelkh MF,Lamb E,et al. Acute Kidney injury in acute on chronic liver failure: Where Does hepatorenal syndrome fit?.Kidney Int,2017,92(5):1058-1070.
[9] Meola M,Nalesso F,Petruccl I,et al. Clinical scenarios in acute kidney injury: Hepatorenal syndrome.Contrib Nephrol,2016,188:33-38.
[10] 李妍,陆伦根.重视肝肾综合征的基础和临床研究.临床肝胆病杂志,2020,36(11):2401-2405.
[11] Mandorfer M,Hecklng M. The renaissance of cholemic nephropathy: A likely underestimated cause of renal dysfunction in l iver disease.Hepatology,2019,69(5):1858-1860.
[12] 史慧敏,李瑞,陈红,等.《2018年欧洲肝病学会失代偿期肝硬化患者的管理临床实践指南》摘译.临床肝胆病杂志,2018,34(8):1632-1638.
[13] 高方博,白朝辉,林苏,等.《2020年英国胃肠病学会与英国肝病学会指南:肝硬化腹水管理》摘译.临床肝胆病杂志,2021,37(2):302-303.
[14] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南.临床肝胆病杂志,2018,34(10):2076-2089.
[15] 刘建军,刘建国,刘常林,等.对《肝硬化肝性脑病诊疗指南》中一个问题的商榷.肝脏,2019,24(6):713-714.
[16] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol,2018,69(2):406-460.
[17] 中华医学会肝病学分会.肝硬化诊治指南.临床肝胆病杂志,2019,35(11):2408-2425.
[18] Patel YR, Kurgansky KE,Imran TF,et al. Prognostic Significance of Baseline Serum Sodium in Heart Failure With Preserved Ejection Fraction.J Am Heart Assoc,2018,7(12):e007529.
[19] 李郑红,董育玮,陆伦根.肝肾综合征发生的危险因素、诊断和最新分型.临床肝胆病杂志,2020,36(11):2411-2414.
[20] Chawla LS,Bellomo R,Blhorac A,et al.Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative(ADQI) 16 Workgroup.2017,13(4):241-257.
[21] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南.临床肝胆病杂志,2018,34(10):2076-2089.
[22] Clchoz-Lach H,Mlchalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.World J Gastroenterol,2013,19(1):26-34.
[23] Renato D,Michel N,Carmelina A,et al. Doea Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis？.J Cin Med Res,2017,9(4):266-272.
[24] Nagueh SF,Smlseth OA,Appleton CP,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of echocardiography and the European Association of cardiovascular imaging.Eur Heart J Cardiovasc Imaging,2016,17(12):1321-1360.
[25] Adebayo D,Neong SF,Wong F. Refractory ascites in Liver cirrhosis.Am J Gastroenterol,2019,114(1):40-47.
[26] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.临床肝胆病杂志,2017,33(10):1847-1863.
[27] Angeli P,Garclatsao G,Nadlm MK,et al. News in pathophysiology,definitionand classification of hepatorenal syndrome: A step beyond the INTERNATIONAL Club of Ascites(ICA) Consensus document.J Hepatol,2019,71(4):811-822.
[28] AmLn AA,Alabsawy EI,Jalan R,et al. Epidemiology,pathophysiology,and management of hepatorenal syndrome.Semin Nephrol,2019,39(1):17-30.
[29] 舒梦妮,李树臣.血清钠对肝硬化失代偿期患者并发症的影响.肝脏,2016,21(1):6-8.
[30] Alukal JJ,John S,Thuluvath PJ .Hyponatremia in cirrhosis: An update.Am J Gastroenterol,2020,115(11):1775-1785.
[31] Wong F,Watson H,Gerbes A,et al. Satavaptan for the management of ascites in cirrhosis: Efficacy and safety across the spectrum of ascites severity.Gut,2012,61(1):108-116.
[32] Martln P,Dlmartlnl A,Feng S,et al. Evaluation for Liver transplantation in adults: 2013 Practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.Hepatology,2014,59(3):1144-1165.
[33] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation.J Hepatol,2016,64(2):433-485.
[34] 中华医学会器官移植学分会.中国肝移植受者选择与术前评估技术规范(2019版).临床肝胆病杂志,2020,36(1):40-43.
[35] Utako P,Emyoo T,Anothalslntawee T,et al. Clinical outcomes after liver transplantion for hepatorenal syndrome: A systematic review and meta analysis. Biomed Res Int,2018,2018:5362810.
[36] Kade G,Lubas A,Spalenlak S,et al. Application of the molecular adsorbent recirculating system in type l hepatorenal syndrome in the course of alcohol related acute on chronic liver failure.Med Sci Monit,2020,26:e923805.
[37] Facclorusso A. Hepatorenal syndrome type 1: Current challenges and future prospect.Ther Clin Risk Manag,2019,27(15):1383-1391. |
